Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey.
暂无分享,去创建一个
[1] J. D. Parkes,et al. Fluctuations of disability in Parkinson's disease – clinical aspects , 1981 .
[2] D. Surmeier,et al. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. , 1998, Advances in pharmacology.
[3] E. Bézard,et al. Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey , 2000, Neuroscience Letters.
[4] M. Inase,et al. Neuronal activity in the primate premotor, supplementary, and precentral motor cortex during visually guided and internally determined sequential movements. , 1991, Journal of neurophysiology.
[5] P. Bédard,et al. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys , 1992, Experimental Neurology.
[6] L. Tremblay,et al. Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism , 1991, Brain Research.
[7] L. Tremblay,et al. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism , 1991, Brain Research.
[8] J. Vitek,et al. Burst and oscillation as disparate neuronal properties , 1996, Journal of Neuroscience Methods.
[9] O. Hassani,et al. Effects of intrasubthalamic injection of dopamine receptor agonists on subthalamic neurons in normal and 6-hydroxydopamine-lesioned rats: an electrophysiological and c-Fos study , 1999, Neuroscience.
[10] B. Levant,et al. Differential distribution of D3 dopamine receptors in the brains of several mammalian species , 1998, Brain Research.
[11] R. Roth,et al. Behavioral Effects of MPTP Administration in the Vervet Monkey , 1994 .
[12] B. Bloch,et al. D1 and D2 dopamine receptor gene expression in the rat striatum: Sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAS in distinct neuronal populations of the dorsal and ventral striatum , 1995, The Journal of comparative neurology.
[13] F. Calon,et al. Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis , 1997, Neuroscience.
[14] E. Bézard,et al. High frequency stimulation of the internal Globus Pallidus (GPi) simultaneously improves parkinsonian symptoms and reduces the firing frequency of GPi neurons in the MPTP-treated monkey , 1996, Neuroscience Letters.
[15] P. Jenner,et al. The rationale for the use of dopamine agonists in Parkinson's disease , 1995, Neurology.
[16] G. Robertson,et al. Pathophysiology of L-dopa-induced dyskinesias. , 1999, Movement Disorders.
[17] M. Merello,et al. Apomorphine induces changes in GPi spontaneous outflow in patients with parkinson's disease , 1999, Movement disorders : official journal of the Movement Disorder Society.
[18] G. E. Alexander,et al. Functional architecture of basal ganglia circuits: neural substrates of parallel processing , 1990, Trends in Neurosciences.
[19] J A Obeso,et al. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. , 2000, Annals of neurology.
[20] P. Bédard,et al. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys , 1996, Brain Research.
[21] R. Desimone,et al. Internal globus pallidus discharge is nearly suppressed during levodopa‐induced dyskinesias , 1999, Annals of neurology.
[22] J G Nutt,et al. Levodopa‐induced dyskinesia , 1990, Neurology.
[23] B. Bloch,et al. Ultrastructural localization of D1 dopamine receptor immunoreactivity in rat striatonigral neurons and its relation with dopaminergic innervation , 1996, Brain Research.
[24] B Bioulac,et al. Effects of l-DOPA on neuronal activity of the globus pallidus externalis (GPe) and globus pallidus internalis (GPi) in the MPTP-treated monkey , 1998, Brain Research.
[25] J. Dostrovsky,et al. Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine. , 2000, Annals of neurology.
[26] GPi Firing rate modification during beginning‐of‐dose motor deterioration following acute administration of apomorphine , 1999, Movement disorders : official journal of the Movement Disorder Society.
[27] B. Gomez-Mancilla,et al. Is striatal dopaminergic receptor imbalance responsible for levodopa‐induced dyskinesia? , 1995, Fundamental & clinical pharmacology.
[28] B Bioulac,et al. Reversal of Rigidity and Improvement in Motor Performance by Subthalamic High‐frequency Stimulation in MPTP‐treated Monkeys , 1993, The European journal of neuroscience.
[29] P. Svenningsson,et al. Dopamine–Adenosine Interactions in the Striatum and the Globus Pallidus: Inhibition of Striatopallidal Neurons through Either D2 or A2A Receptors Enhances D1Receptor-Mediated Effects on c-fos Expression , 1997, The Journal of Neuroscience.
[30] P. Sokoloff,et al. Novel dopamine receptors half a decade later. , 1995, Trends in pharmacological sciences.
[31] H. Akil,et al. Localization of dopamine D2 receptor mRNA and D1 and D2 receptor binding in the rat brain and pituitary: an in situ hybridization- receptor autoradiographic analysis , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[32] H. Bergman,et al. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. , 1994, Journal of neurophysiology.
[33] F. Durif. Treating and Preventing Levodopa-Induced Dyskinesias , 1999, Drugs & aging.
[34] M. Woodruff,et al. Toxin-Induced Models of Neurological Disorders , 1994, Springer US.
[35] C. Gerfen,et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. , 1990, Science.
[36] P. Blanchet,et al. Dyskinesia and wearing‐off following dopamine D1 agonist treatment in drug‐naive 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned primates , 1996, Movement disorders : official journal of the Movement Disorder Society.
[37] A. Benazzouz,et al. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. , 1995, European journal of pharmacology.
[38] E. Bézard,et al. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms , 1999, The European journal of neuroscience.
[39] S. Iversen,et al. Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. , 1990, Clinical neuropharmacology.
[40] P. Jenner,et al. An appraisal of the antiparkinsonian activity of piribedil in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmosets , 1996, Movement disorders : official journal of the Movement Disorder Society.
[41] E. Bézard,et al. Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental Parkinsonism , 1997, Neuroscience.
[42] B Bioulac,et al. Ratio of inhibited-to-activated pallidal neurons decreases dramatically during passive limb movement in the MPTP-treated monkey. , 2000, Journal of neurophysiology.
[43] E. Bézard,et al. Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey , 2000, Journal of Neuroscience Methods.
[44] D. Guehl,et al. High-frequency stimulation of the globus pallidus internalis in Parkinson's disease: a study of seven cases. , 1997, Journal of neurosurgery.
[45] J. Dostrovsky,et al. Effects of apomorphine on globus pallidus neurons in parkinsonian patients , 1997, Annals of neurology.